Mink presents clinical data at sitc 2022 showcasing inkt cell therapy pipeline

New york, nov. 10, 2022 (globe newswire) --  mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced the presentation of new data from five presentations at the 2022 society for immunotherapy of cancer (sitc) annual meeting.
INKT Ratings Summary
INKT Quant Ranking